Neoadjuvant Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is a phase II study to determine the safety and efficacy of tislelizumab when given in
combination with nab-paclitaxel as neoadjuvant treatment in patients with muscle-invasive
bladder cancer (MIBC) prior to cystectomy or complete TURBT. Patients will receive
neoadjuvant treatment with tislelizumab in combination with nab-paclitaxel every 3 weeks for
3 treatment cycles over 9 weeks followed by standard radical cystectomy or complete TURBT.